Dataset on cost-analysis of medication deprescribing scenarios for older adult coverage under public drug benefit programs in Canada

The dataset covers the equations and procedure used for the estimation of an older adult's total annual medication costs, across Canadian provinces and territories; detailed to report pharmacy margin, government share, and patient share. We presented a case of an older adult using 10 different medications commonly used, according to Canadian Institute for Health Information. Eight different deprescribing scenarios were created, based on recommendations from Beers Criteria and the Canadian Deprescribing Network, for the purpose of comparing the cost difference before and after each intervention on pharmacies, patients, and governments. Scenarios included: (1) Stopping an over the counter medication; (2) Discontinuation of a medication; (3) Slow taper of a potentially inappropriate medication; (4) Rapid taper of a potentially inappropriate medication; (5) Switching to safer medication; (6) Dose reduction; (7) Switching to a lower cost medication; (8) Changing from combination to a single medication. The data presented are related to the article entitled “Financial advantage or barrier when deprescribing for seniors: A case based analysis” [1]


a b s t r a c t
The dataset covers the equations and procedure used for the estimation of an older adult's total annual medication costs, across Canadian provinces and territories; detailed to report pharmacy margin, government share, and patient share. We presented a case of an older adult using 10 different medications commonly used, according to Canadian Institute for Health Information. Eight different deprescribing scenarios were created, based on recommendations from Beers Criteria and the Canadian Deprescribing Network, for the purpose of comparing the cost difference before and after each intervention on pharmacies, patients, and governments. Scenarios included: (1) Stopping an over the counter medication; (2) Discontinuation of a medication; (3) Slow taper of a potentially inappropriate medication; (4) Rapid taper of a potentially inappropriate medication; (5) Switching to safer medication; (6) Dose reduction; (7) Switching to a lower cost medication; (8) Changing from combination to a single medication. The data presented are related to the article entitled "Financial advantage or barrier when deprescribing for seniors: A case based analysis" [1] © For dispensing fee if not fixed, then it was drug pricing related (using max government allowable fees) Description of data collection In each province and territory, we calculated for each medication: (1) the mark-up, for prescription medication the mark-up was obtained from ministries websites, and for over the counter medication was calculated as the difference between an established wholesaler's list price (i.e. cost to pharmacy) and the same wholesaler's published manufacturer's suggested retail price. This resulted in a 35% gross margin to the pharmacy.
(2) pharmacy margin, as dispensing fee plus mark up (

Value of the Data
• The data provide comparison of deprescribing cost-impact on three payers: the pharmacy, the patient, and the government • Pharmaceutical policy-makers can use this model for further research concerning deprescribing cost analysis over a wider age group. • The dataset highlights different costing criteria among Canadian public drug programs concerning older adults' coverage.

Data description
The Baseline dataset, includes cost analysis of the provided case scenario among all Canadian provinces and territories before any deprescribing intervention. The patient eligibility for coverage under provincial drug programs was based on his annual income, as previously described. [  The following eight datasets , provide each deprescribing scenario and the following cost implications. Each scenario is calculated for each province and territory in Canada, and includes the drug costs for the patient, government, and pharmacy.

[See Supplementary Tables]
The result dataset, includes two tables; Table 1 was generated by calculating for each of the eight scenarios the mean difference of pharmacy margin, government share and patient share from the basic medication cost before the deprescring scenarios. Table 2 was calculated as the percentages of each scenario mean difference that was generated in table-1 from the average mean in terms of pharmacy margin, government share and patient share. All the calculations are in Canadian dollars.

Experimental design, materials, and methods
The study methods have been described previously [1] . While information regarding drug costs was accessible from provincial and territorial Ministry of Health electronic websites, some data was not available and the following calls were made to complete the required dataset: Province: Manitoba

. Baseline Annual Medication Costs in Canadian Dollars
A case study representing an average older adult in Canada, with common comorbidities and medications, was developed. The case scenario and medication regimen are listed below.
The baseline cost and change in cost on each payer for the 8 scenarios is shown in the following Figures